Dosage and administration
Apply liberally to face and neck in the morning.
Apply liberally to face and neck in the morning.
For external use only. Avoid contact
with eyes. If contact occurs, rinse eyes thoroughly
with water. Discontinue use if irritation or rash appears.
Keep out of reach of children. In case of accidental
ingestion, seek professional assistance or contact
a Poison Control Center immediately.
Apply liberally to face and neck in the morning.
in a 1.7 oz / 50mL airless pump.
Homosalate 7%, Octocrylene, 6%,
Octisalate 5%, Avobenzone 3%
Sunscreen
Water (Aqua), Isododecane, Hydrogenated
Polydecene, Glycerin, Glyceryl Stearate, Arachidyl
Alcohol, Behenyl Alcohol, Bis (Tripeptide-1) Copper
Acetate, Plankton Extract, Triticum Vulgare (Wheat)
Gluten Extract, Glycine Soja (Soybean) Seed Extract,
Dimethicone, Arachidyl Glucoside, Caprylyl Glycol,
Xanthan Gum, Cetyl Alcohol, PEG-100 Stearate, Prunus
Armeniaca (Apricot) Kernal Oil, Squalane, Ammonium
Acrylate/Acrylamide Copolymer, Polyisobutene, Polysorbate
20, Sodium Hydroxide, Lecithin, Sodium
Chloride, Phenoxyethanol, Sorbic Acid. May Contain
+/- Ultramarines.
DayTherapyFoilPacket.jpg PacketHolderDayTherapypg1.jpg PacketHolderDayTherapypg2.jpg PkgInsertComboTherapypg1.jpg PkgInsertComboTherapypg2.jpg
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 62362-184-03 | 2019-11-13 | C162847 | 48780-1 | 97449f38-cc68-f6ea-e053-dbdaa90aa703 | Neova Day Therapy - SPF 30 - 2ML - 0.07 FL. OZ - package insert |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 62362-184-03 | Neova Day TherapySPF 30 | 1 in 1 POUCH | LOTION | 1 | 4 | |
| 62362-184-07 | Neova Day TherapySPF 30 | 2 mL in 1 PACKAGE | LOTION | 2 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 4 | |
| Homosalate | ACTIVE INGREDIENT | V06SV4M95S | 4 | |
| Octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 4 | |
| Octocrylene | ACTIVE INGREDIENT | 5A68WGF6WM | 4 | |
| Avobenzone | ACTIVE MOIETY | G63QQF2NOX | 4 | |
| Homosalate | ACTIVE MOIETY | V06SV4M95S | 4 | |
| Octisalate | ACTIVE MOIETY | 4X49Y0596W | 4 | |
| Octocrylene | ACTIVE MOIETY | 5A68WGF6WM | 4 | |
| Apricot Kernel Oil | INACTIVE INGREDIENT | 54JB35T06A | 4 | |
| Arachidyl Alcohol | INACTIVE INGREDIENT | 1QR1QRA9BU | 4 | |
| Arachidyl Glucoside | INACTIVE INGREDIENT | 6JVW35JOOJ | 4 | |
| Caprylyl Glycol | INACTIVE INGREDIENT | 00YIU5438U | 4 | |
| Cetyl Alcohol | INACTIVE INGREDIENT | 936JST6JCN | 4 | |
| Dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 4 | |
| Docosanol | INACTIVE INGREDIENT | 9G1OE216XY | 4 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| Glyceryl Monostearate | INACTIVE INGREDIENT | 230OU9XXE4 | 4 | |
| Hydrogenated Polydecene (550 MW) | INACTIVE INGREDIENT | U333RI6EB7 | 4 | |
| Isododecane | INACTIVE INGREDIENT | A8289P68Y2 | 4 | |
| Lecithin, Soybean | INACTIVE INGREDIENT | 1DI56QDM62 | 4 | |
| PEG-100 Stearate | INACTIVE INGREDIENT | YD01N1999R | 4 | |
| Phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 4 | |
| Polyisobutylene (1300 MW) | INACTIVE INGREDIENT | 241BN7J12Y | 4 | |
| Polysorbate 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 4 | |
| Prezatide Copper Acetate | INACTIVE INGREDIENT | A3LEI4P1NB | 4 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | 4 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 4 | |
| Sorbic Acid | INACTIVE INGREDIENT | X045WJ989B | 4 | |
| Soybean | INACTIVE INGREDIENT | L7HT8F1ZOD | 4 | |
| Squalane | INACTIVE INGREDIENT | GW89575KF9 | 4 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 4 | |
| Xanthan Gum | INACTIVE INGREDIENT | TTV12P4NEE | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 62362-184 | 62362-184-07, 62362-184-03 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | LIQUID / ORAL | 2 mg/5ml | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / ENDOTRACHEAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RECTAL | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTERSTITIAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAVASCULAR | ADJ PH | ||
| Polysorbate 20 | POLYSORBATE 20 | 7T1F30V5YH | CREAM / TOPICAL | 108 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| Lecithin, Soybean | SOYBEAN LECITHIN | 1DI56QDM62 | TABLET, EXTENDED RELEASE / ORAL | 20 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| Squalane | SQUALANE | GW89575KF9 | CREAM / TOPICAL | 6 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CONCENTRATE / ORAL | 10 mg/5ml | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAVENOUS | 6320 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, DELAYED RELEASE / ORAL | 6 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / AURICULAR (OTIC) | 18 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRADISCAL | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / DENTAL | 0.4 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRASYNOVIAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRALESIONAL | ADJ PH | ||
| Soybean | SOYBEAN | L7HT8F1ZOD | CAPSULE / ORAL | NA | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / TOPICAL | ADJ PH | ||
| Phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAMUSCULAR | 1486 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 0.86 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / TOPICAL | 0.2 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, COATED / ORAL | 0.08 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRAVENOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRA-ARTICULAR | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 226 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / ORAL | 148 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAUDAL | 210 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| Glyceryl Monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | JELLY / TOPICAL | ADJ PH | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Polysorbate 20 | POLYSORBATE 20 | 7T1F30V5YH | TABLET, EXTENDED RELEASE / ORAL | 4.2 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SOLUTION / ORAL | 10 mg/5ml | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOAP / TOPICAL | 1.26 %w/w | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / PARENTERAL | 210 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION / ORAL | 360 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| Cetyl Alcohol | CETYL ALCOHOL | 936JST6JCN | CREAM / VAGINAL | 200 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION / ORAL | 450 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / AURICULAR (OTIC) | 18 mg | ||
| Sodium Chloride | SODIUM CHLORIDE | 451W47IQ8X | SUPPOSITORY / RECTAL | 140 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a752b6e4-63cd-4812-9e70-82829e1a72dd | 2d320c79-9d09-424e-9f60-789ca2a75373 | 2012-01-11 | Warnings | a752b6e4-63cd-4812-9e70-82829e1a72dd 2d320c79-9d09-424e-9f60-789ca2a75373 |
Adverse event summaries are temporarily unavailable. Other product information remains available.